Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats
We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x 10(5) or 5 x 10(6) TE-671 human rhabdomyosarcoma cells or 5...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 54; no. 17; pp. 4710 - 4714 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.09.1994
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x 10(5) or 5 x 10(6) TE-671 human rhabdomyosarcoma cells or 5 x 10(6) D-54 MG human glioma cells and were treated with melphalan on days 8, 5, or 5, respectively. Melphalan toxicity in nontumor-bearing rats was assessed at single doses of a 2.0, 3.0, 4.0, or 5.0 mM solution, with clinical and histological evidence of neurotoxicity observed at the 4.0 and 5.0 mM levels. Multiple-dose toxicity studies using a dosing schedule of twice a week for two weeks with a 0.25, 0.5, 0.75, 1.0, 1.5, or 2 mM solution revealed dose-dependent clinical and histological evidence for toxicity at all dosages. Treatment of TE-671 with a single dose of 2.0 mM intrathecal melphalan produced an increase in median survival of 442% compared with saline controls (P < 0.003). Comparison of a single dose of 1.0 or 2.0 mM melphalan with a multiple dose regimen at 0.25 or 0.5 mM melphalan in the treatment of TE-671 revealed increases in median survival of 50% for 1.0 mM, 57% for 2.0 mM, 79% for 0.5 mM, and 111% for 0.25 mM concentrations. Comparison of a single dose of 1 mM melphalan with multiple doses of 0.25 mM melphalan in the treatment of D-54 MG revealed an increase in median survival of 475+% for each of the regimens. Intrathecal melphalan may be an important new addition in the treatment of neoplastic meningitis and is currently being evaluated clinically in a Phase 1 trial. |
---|---|
AbstractList | We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats. Animals received injections via chronic indwelling subarachnoid catheters with 5 x 10(5) or 5 x 10(6) TE-671 human rhabdomyosarcoma cells or 5 x 10(6) D-54 MG human glioma cells and were treated with melphalan on days 8, 5, or 5, respectively. Melphalan toxicity in nontumor-bearing rats was assessed at single doses of a 2.0, 3.0, 4.0, or 5.0 mM solution, with clinical and histological evidence of neurotoxicity observed at the 4.0 and 5.0 mM levels. Multiple-dose toxicity studies using a dosing schedule of twice a week for two weeks with a 0.25, 0.5, 0.75, 1.0, 1.5, or 2 mM solution revealed dose-dependent clinical and histological evidence for toxicity at all dosages. Treatment of TE-671 with a single dose of 2.0 mM intrathecal melphalan produced an increase in median survival of 442% compared with saline controls (P < 0.003). Comparison of a single dose of 1.0 or 2.0 mM melphalan with a multiple dose regimen at 0.25 or 0.5 mM melphalan in the treatment of TE-671 revealed increases in median survival of 50% for 1.0 mM, 57% for 2.0 mM, 79% for 0.5 mM, and 111% for 0.25 mM concentrations. Comparison of a single dose of 1 mM melphalan with multiple doses of 0.25 mM melphalan in the treatment of D-54 MG revealed an increase in median survival of 475+% for each of the regimens. Intrathecal melphalan may be an important new addition in the treatment of neoplastic meningitis and is currently being evaluated clinically in a Phase 1 trial. |
Author | SAVINA, P. A GUASPARI, A BLUM, R FRIEDMAN, H. S SCHUSTER, J. M MCLENDON, R. E FUCHS, H. E ARCHER, G. E BIGNER, D. D COLVIN, O. M |
Author_xml | – sequence: 1 givenname: H. S surname: FRIEDMAN fullname: FRIEDMAN, H. S organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 2 givenname: G. E surname: ARCHER fullname: ARCHER, G. E organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 3 givenname: R. E surname: MCLENDON fullname: MCLENDON, R. E organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 4 givenname: J. M surname: SCHUSTER fullname: SCHUSTER, J. M organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 5 givenname: O. M surname: COLVIN fullname: COLVIN, O. M organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 6 givenname: A surname: GUASPARI fullname: GUASPARI, A organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 7 givenname: R surname: BLUM fullname: BLUM, R organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 8 givenname: P. A surname: SAVINA fullname: SAVINA, P. A organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 9 givenname: H. E surname: FUCHS fullname: FUCHS, H. E organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States – sequence: 10 givenname: D. D surname: BIGNER fullname: BIGNER, D. D organization: Duke univ. medical cent., dep. pediatrics, Durham NC 27710, United States |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4206768$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/8062269$$D View this record in MEDLINE/PubMed |
BookMark | eNo9T8tqwzAQFCUlddJ-QkGHXg2rl2UdS-gjEAiF9hw2llyr2LKx7IP_voKanpZ57AyzI5vQB3dDMqZEmWsp1YZkAFDmSmp-R3Yx_iSoGKgt2ZZQcF6YjHwcwzTi1LgKW9q5dmiwxUATMeKw0L6mzdwlIrh-aDFOvkqu4MO3n3ykPtD0u3SJDbN1NCXFe3JbYxvdw3r35Ov15fPwnp_Ob8fD8ylvUvGUG8GkEkyjqOxVMgfcCqUMOgmGCawFgrUSkBkDjGtbu4QLhlpwJsE6sSePf7nDfO2cvQyj73BcLuu0pD-tOsY0rh4xVD7-2ySHQhel-AVLqVo9 |
CODEN | CNREA8 |
ContentType | Journal Article |
Copyright | 1994 INIST-CNRS |
Copyright_xml | – notice: 1994 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 4714 |
ExternalDocumentID | 8062269 4206768 |
Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
GrantInformation_xml | – fundername: NINDS NIH HHS grantid: NS 30245 – fundername: NCI NIH HHS grantid: CA 56115 – fundername: NCI NIH HHS grantid: CA 11898 |
GroupedDBID | --- -ET .55 .GJ 08R 18M 29B 2WC 34G 39C 3O- 476 53G 5GY 5RE 5VS 6J9 8WZ A6W AAPBV AAUGY ABOCM ABPTK ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CS3 D0S DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 IQODW J5H KQ8 L7B LSO MVM OHT OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WH7 WHG WOQ X7M XFK XJT YKV YZZ ZA5 ZCG ZGI CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-h269t-93145317a3cdb41e02d3559ae40913af3a0dd40a1990127dfe0dd61a732140de3 |
ISSN | 0008-5472 |
IngestDate | Sat Sep 28 07:32:18 EDT 2024 Sun Oct 29 17:10:00 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Keywords | Antineoplastic agent Human Nervous system diseases Rat Rodentia Single dose Malignant tumor Intrathecal administration Multiple dose Vertebrata Alkylating agent Chemotherapy Mammalia Treatment Meningeal carcinomatosis Animal Nitrogen mustard |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-h269t-93145317a3cdb41e02d3559ae40913af3a0dd40a1990127dfe0dd61a732140de3 |
PMID | 8062269 |
PageCount | 5 |
ParticipantIDs | pubmed_primary_8062269 pascalfrancis_primary_4206768 |
PublicationCentury | 1900 |
PublicationDate | 1994-09-01 |
PublicationDateYYYYMMDD | 1994-09-01 |
PublicationDate_xml | – month: 09 year: 1994 text: 1994-09-01 day: 01 |
PublicationDecade | 1990 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 1994 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
SSID | ssj0005105 |
Score | 1.5812294 |
Snippet | We report the activity and toxicity of intrathecal melphalan in the treatment of human neoplastic meningitis in the subarachnoid space of athymic nude rats.... |
SourceID | pubmed pascalfrancis |
SourceType | Index Database |
StartPage | 4710 |
SubjectTerms | Animals Antineoplastic agents Biological and medical sciences Brain Neoplasms - drug therapy Brain Neoplasms - mortality Chemotherapy Demyelinating Diseases - chemically induced Disease Models, Animal Drug Screening Assays, Antitumor Female Glioma - drug therapy Glioma - mortality Humans Injections, Spinal Medical sciences Melphalan - administration & dosage Melphalan - adverse effects Meningitis - drug therapy Meningitis - etiology Meningitis - mortality Pharmacology. Drug treatments Rats Rats, Nude Rhabdomyosarcoma - drug therapy Rhabdomyosarcoma - mortality Subarachnoid Space Transplantation, Heterologous Tumor Cells, Cultured |
Title | Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats |
URI | https://www.ncbi.nlm.nih.gov/pubmed/8062269 |
Volume | 54 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELYKB8QF8VgEy4J84IYSJY0TJ0dUCuVRENBK3JATOwKpCitID7v3_d_M2E5iEBILl6hxnSjxfBmPx9_MELIfF7CQlop5RSkDj4WF8NJMcPiuwNhnEvfKMDh5fJmMpuzsLr7r9f45rKV5nfvF3w_jSr4jVWgDuWKU7Bck294UGuA3yBeOIGE4_peMT9EzCxZcoUNAMGp2JrTvHxMFaDNQu-grZIkLTMgMvUyFokdNg4Vr_yA3vppLdQB3enFN1QHi4fnAZgN60Nu9hreh9cps5jtehOOb0-HR-FBzBkZ-50_FvSjDtTjxu6CH8eBieHl0pXvfOO23g9H0dmL6n_nWUSttjB5rOVe1EwUAr-cgTJMm7YM3nMI3ejn1YmaK-PiqU8WcmWSTja42CacbTHJH88IkGzizOJyyboprtvXfzXwtH5FhEvskXSALUYi80PPrLuV8bHmwzSMie1a8gGBLU_nk3XpE2yWTVbJiFxT00KBjjfRUtU6WxpYysUGuHZDQFiTUgoQ-lVSDhHYgoR1I6GNFLUgogoQiSH6Q6fFwMhh5to6G99BPstrLopCBquUiKmTOQhX0JViZmVAMk8KKMhKBlCwQIe6R9rksFZwnoeBYxAo-5GiTLFZPldoitMzBluEFj4oQ69RwEec8SwVjURTD3Kq2ye6bwbn_bXKm3NsR3iabZrDaP9IggRVA9vOTC3fIcoe0X2Sxfp6rXTAH63xPi-sVSkNhzw |
link.rule.ids | 315,786,790 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intrathecal+melphalan+therapy+of+human+neoplastic+meningitis+in+athymic+nude+rats&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=FRIEDMAN%2C+H.+S&rft.au=ARCHER%2C+G.+E&rft.au=MCLENDON%2C+R.+E&rft.au=SCHUSTER%2C+J.+M&rft.date=1994-09-01&rft.pub=American+Association+for+Cancer+Research&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=54&rft.issue=17&rft.spage=4710&rft.epage=4714&rft.externalDBID=n%2Fa&rft.externalDocID=4206768 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |